Navigation Links
WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
Date:11/21/2011

85,025$

1,454,920Cost of revenue492,246312,047647,137583,796Gross profit (loss)(403,158)321,194(162,112)871,124Operating expenses:Sales and marketing913,948653,3222,550,1071,378,271Research and development1,900,4172,047,3675,980,3055,086,078General and administrative1,259,2111,248,7734,747,9923,452,727Total operating expenses4,073,5763,949,46213,278,4049,917,076Operating loss(4,476,734)(3,628,268)(13,440,516)(9,045,952)Other income and (expenses):Interest income6,8437,96514,20315,072Interest expense (including excess debt discount of $2,255,074 expensed as interest in the nine months ended September 30, 2011)(240,143)(280)(3,059,370)(1,954)Gain on revaluation of conversion element of Series B redeemable convertible preference shares of subsidiary, net35,615124,473111,227124,473Gain on revaluation of conversion element of convertible promissory notes, net7,525,265--5,912,152--Gain (loss) on revaluation of warrants, net1,064,096(1,665,950)1,363,70314,526Liquidated damages for late S-1 registration(532,161)--(532,161)--Miscellaneous income (expense)214,843(62,703)197,593(135,697)Total other income and (expenses)8,074,358(1,596,495)4,007,34716,420Net income (loss) before provision for income taxes3,597,624(5,224,763)(9,433,169)(9,029,532)Provision for income taxes16,703--(713)--Net income (loss)3,580,921(5,224,763)(9,432,456)(9,029,532)Accretion on Series A and B redeemable convertible preference shares of subsidiary associated with premium(166,773)(79,151)(287,929)(223,464)Accretion on Series B redeemable convertible preference shares of subsidiary associated with bifurcation of conversion element--(428,787)--(428,787)Accretion on Series A-1 convertible preferred stock associated with beneficial conversion feature----(9,250,009)--Series A-1 preferred dividend(191,866)--(266,119)--Net income (loss) attributable to common stockholders

$

3,222,282$

(5,732,701)$

(19,236,513)$

(9,681,783)Net income (loss) pe
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
2. WaferGen Announces $30 Million Financing
3. WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing
4. WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels
5. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
6. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
7. WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System
8. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
9. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
10. WaferGen Closes on Private Financings of Approx. $6.2 Million
11. WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens, today announced that ... Jaffray  26 th Annual Healthcare Conference on December 2, ... The New York Palace in New York, NY ... concerning the Company, its operations, strategies and prospects may be ...
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 /PRNewswire/ ... company focused on developing diagnostic tests for cancer and other ... study will be presented at the Science for Business BioWin ... Belgium . The data come from VolitionRx,s lung ... the Pneumology department of the Centre Hospitalier Universitaire (CHU) de ...
(Date:11/24/2014)... November 24, 2014 Continental Clinical ... populations into clinical trials at its mid-Atlantic late-phase ... “Continental was created with the idea of closing ... fundamental role in medical advances," said Continental's CEO, ... experiment to the immortal cell line of Henrietta ...
(Date:11/24/2014)... , November 24, 2014 ... Workflow, honored for dynamic leadership skills, business acumen ... technical and medical information products and services, congratulates ... for Clinical Reference and Workflow, Elsevier Clinical Solutions, for ... Worth Watching ® Awards issue of Profiles ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3
... 6 Axelar AB today announced successful,completion of ... phase I/II,clinical trial on cancer patients with its ... inhibitor which has no effects,on the closely related ... on,patients having terminal cancer disease. The results showed ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and,innovative anti-cancer pharmaceuticals in China, announced today that ... on Monday, May 18, 2009,after the market closes ... Ren, and chief financial officer, Frank Zhigang Zhao, ...
... 5 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today ... For the first quarter of 2009, the Company reported a ... a net loss of $21.1 million, or $0.55 per share, for ... 2009 were $0.7 million compared with $1.8 million for the same ...
Cached Biology Technology:Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009 2Neurocrine Biosciences Reports First Quarter 2009 Results 2Neurocrine Biosciences Reports First Quarter 2009 Results 3Neurocrine Biosciences Reports First Quarter 2009 Results 4Neurocrine Biosciences Reports First Quarter 2009 Results 5Neurocrine Biosciences Reports First Quarter 2009 Results 6Neurocrine Biosciences Reports First Quarter 2009 Results 7Neurocrine Biosciences Reports First Quarter 2009 Results 8
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... issue of Genes & Development, Dr. Karlene Cimprich and ... structure sufficient to activate the ATR-mediated DNA damage checkpoint. ... says Dr. Cimprich. "The ability to precisely define and ... an experimental system will enable us to control, quantitative ...
... one cause of high blood pressure lies within the brain, ... forward by scientists at the University of Bristol, UK, and ... Hidefumi Waki, working in a research group led by Professor ... JAM-1 (junctional adhesion molecule-1), which is located in the walls ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
Cached Biology News:Blame the brain for high blood pressure 2MU researcher placing eye implants in cats to help humans see 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: